Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies

计划入组 23 人 · 首次发布于 2016 年 9 月 23 日

Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency

计划入组 120 人 · 首次发布于 2018 年 7 月 9 日

Paclitaxel and TAK-228 in Urothelial Carcinoma

计划入组 52 人 · 首次发布于 2018 年 11 月 19 日

PI3K/mTOR Inhibitor 8o

dual PI3K/mTOR inhibitors (cancer)

wortmannin-conjugate PI3K/mTOR inhibitors (Wyeth)

Pathway Therapeutics, Inc.

United States

Erasca

United States

Eledon Pharmaceuticals

United States

Sensei Biotherapeutics Acquires Faeth Therapeutics for $200M to Advance PI3K/AKT/mTOR Pathway Inhibitor PIKTOR

Faeth Therapeutics Advances Novel Three-Pronged Approach for Metabolism-Driven Cancers with Promising Preclinical Results

Palvella Therapeutics Receives FDA Grant for Phase 3 Trial of QTORIN Rapamycin in Microcystic Lymphatic Malformations